Actualités

On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc. (NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market. The obesity-focused biotech raised more than $600 million in April through an initial public offering of 39.06 million shares priced at $16 each. Kailera Portfolio ‘Strongly Mirrors’ Eli Lilly William Blair analyst Andy Hsieh said Kailera’s obesity pipeline could position the company as a future challenger in the expanding weight-loss market, ci

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.

Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were able to maintain significant weight loss after switching from higher-dose injectable incretin therapies to either Foundayo or lower-dose Zepbound. • Eli Lilly stock is showing upward bias. What should traders watch with LLY? The company presented data from the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN studies at the 33rd European Congress on Obesity. The findings were also p

Micron Technology is on pace to close above the $900 billion market value for the first time, according to Dow Jones Market Data. The semiconductor company, whose stock is up 4.8% today, is on pace to become the 11th largest U.S. company by market cap.

ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care.

FEATURE Micron Technology stock was gaining early Wednesday. Labor unrest at Samsung Electronics could intensify the memory-chip supply crunch.  Micron shares were up 3.1% in early trading. Talks between Samsung and its labor union to avert a walkout collapsed on Wednesday.

If it feels like growth stocks can’t continue their outperformance much longer, ignore that feeling. The Vanguard S&P 500 Growth Index Fund Exchange-Traded Fund, home to companies with high sales growth including Nvidia Advanced Micro Devices Microsoft and Eli Lilly is up 13% in the past month. A couple of factors have driven the performance of the growth stocks.

Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO and Mondelez have been highlighted in this Investment Ideas article.

While the company has more publicly highlighted its AI developments in Europe, onboarding Vipin Gopal indicates its US division is ready to do more with this tech.

Eli Lilly (NYSE:LLY) reported new late phase clinical data on its obesity portfolio. Patients with obesity maintained significant long term weight loss after switching from injectable to oral therapies. The trials highlighted Foundayo and Zepbound as durable options for ongoing weight management and showed a consistent safety profile for the new oral GLP 1 therapy. Eli Lilly enters this update with its stock at $989.87 and 5 year share price gains of 432.2%. The company has also delivered a...

Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.

Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year

These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare.

Moby summary of Hims & Hers Health, Inc.'s Q1 2026 earnings call

A spike in facility sales to outsourcing companies points to an industry need for greater flexibility.

The market adage “Sell in May and Go Away” rarely fits a single name cleanly. Eli Lilly (NYSE: LLY) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim. The Setup: A ... Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom

Eli Lilly's Omvoh (mirikizumab) has shown durable disease clearance over four years in patients with moderately to severely active ulcerative colitis. The long term data adds to existing evidence on Omvoh's efficacy and safety in inflammatory bowel disease. The results reinforce Eli Lilly's position in immunology and provide new information for clinicians and patients considering chronic treatment options. Eli Lilly (NYSE:LLY) enters this update with Omvoh's four year results adding another...

Exploring PRIMECAP Management (Trades, Portfolio)'s Recent 13F Filing and Investment Strategies

The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Eli Lilly and Company is one of the best cancer stocks. TheFly reported on May 5 that Barclays increased its valuation outlook for LLY, raising the price target to $1,400 from $1,350 while maintaining an Overweight rating. The […]

The tech sector has a record-high market cap of over $23 trillion, a 37% weighting in the S&P 500, the largest percentage ever.

Eli Lilly faces challenges in the GLP-1 market, with Novo Nordisk gaining a timing advantage in both injectable and oral drug approvals.

If it feels like growth stocks can’t continue their outperformance much longer, ignore that feeling. The Vanguard S&P 500 Growth Index Fund Exchange-Traded Fund, home to companies with high sales growth including Nvidia Advanced Micro Devices Microsoft and Eli Lilly is up 13% in the past month. A couple of factors have driven the performance of the growth stocks.

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Eli Lilly CFO Lucas Montrace joins Ashley Mastronardi on NYSE Live to discuss his YOY Revenue Beat

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story. Blowout Quarter Meets a Methodical Rebuild Lilly’s Q1 2026 ... Pfizer vs Eli Lilly: Different Bets on Pharma M&A